Active ingredients: venetoclax
What it is used for
Acute Myeloid Leukaemia,VENCLEXTA, as part of combination therapy, is indicated for the treatment of newly diagnosed adult patients with Acute Myeloid Leukaemia (AML) who are ineligible for intensive chemotherapy.,This medicine has provisional approval in Australia for the treatment of newly diagnosed patients with AML who are ineligible for intensive chemotherapy. The decision to approve this indication has been made on the basis of interim data (overall response rate and duration of response). Continued approval of this indication depends on verification and description of benefit in confirmatory trials.,Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma,VENCLEXTA in combination with obinutuzumab is indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who are considered unfit or unsuitable for chemo-immunotherapy.,VENCLEXTA in combination with rituximab is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.,VENCLEXTA monotherapy is indicated for the treatment of: patients with relapsed or refractory CLL with 17p deletion, or patients with relapsed or refractory CLL for whom there are no other suitable treatment options.
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 30 degrees Celsius
- Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Oblong, biconvex shaped, pale yellow debossed with V on one side and 100 on the other side.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on July 1, 2020. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient venetoclax
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.